Xiao-Tang Kong

Title(s)Health Sciences Professor, Neurology
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-6208
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report. Per Med. 2024 Jan 26. Yuen CA, Bao S, Aung MS, Shishodia R, Kong XT. PMID: 38275171.
      View in: PubMed   Mentions:    Fields:    
    2. Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. J Exp Clin Cancer Res. 2022 Dec 14; 41(1):344. Bota DA, Taylor TH, Piccioni DE, Duma CM, LaRocca RV, Kesari S, Carrillo JA, Abedi M, Aiken RD, Hsu FPK, Kong XT, Hsieh C, Bota PG, Nistor GI, Keirstead HS, Dillman RO. PMID: 36517865; PMCID: PMC9749349.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    3. Adherence to Prophylactic Anticonvulsant Guidelines for Newly Diagnosed Brain Tumor Patients: A Quality Improvement Study. J Adv Pract Oncol. 2022 Nov; 13(8):775-789. Fu DB, Kong XT, Veenema TG, Bota DA, Koirala B. PMID: 36727021; PMCID: PMC9881735.
      View in: PubMed   Mentions:
    4. A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide. Front Oncol. 2022; 12:934638. Bota DA, Taylor TH, Lomeli N, Kong XT, Fu BD, Schönthal AH, Singer S, Blumenthal DT, Senecal FM, Linardou H, Rokas E, Antoniou DG, Schijns VEJC, Chen TC, Elliot J, Stathopoulos A. PMID: 35837107; PMCID: PMC9273968.
      View in: PubMed   Mentions: 1  
    5. A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas. Front Neurol. 2020; 11:373. Hrachova M, Nguyen ENT, Fu BD, Dandekar MJ, Kong XT, Cadena G, Hsu FPK, Billimek J, Taylor TH, Bota DA. PMID: 32435228; PMCID: PMC7218113.
      View in: PubMed   Mentions: 6  
    6. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. CNS Oncol. 2018 07 01; 7(3):CNS22. Bota DA, Chung J, Dandekar M, Carrillo JA, Kong XT, Fu BD, Hsu FP, Schönthal AH, Hofman FM, Chen TC, Zidovetzki R, Pretto C, Strik A, Schijns VE, Stathopoulos A. PMID: 30157683; PMCID: PMC6200061.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCellsCTClinical Trials
    7. Intracranial meningioma with carcinoma tumor-to-tumor metastasis: two case reports. CNS Oncol. 2018 04; 7(2):CNS09. Pham JT, Kim RC, Nguyen A, Bota D, Kong XT, Vadera S, Hsu F, Carrillo JA. PMID: 29698064; PMCID: PMC5977278.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    8. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1195-1203. Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, Lai A. PMID: 29722661; PMCID: PMC6277207.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    9. Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia. Case Rep Neurol. 2017 Jan-Apr; 9(1):114-120. Tran PN, Kong XT. PMID: 28559835; PMCID: PMC5437478.
      View in: PubMed   Mentions: 2  
    Xiao-Tang's Networks
    Concepts (33)
    Derived automatically from this person's publications.
    Co-Authors (14)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department